Quick Links

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an independent educational grant from Amgen.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know

Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know

Wednesday, April 10, 2019

7:00 PM - 9:00 PM
Dinner and Registration: 6:30 PM - 7:00 PM

Philadelphia Marriott Downtown
Franklin Hall 8 - 10
1201 Market Street
Philadelphia, PA 19107


While statins have been the cornerstone of hypercholesterolemia treatment for over 30 years, a relatively large segment of this population remains at residual cardiovascular disease (CVD) risk, despite statin therapy. This may be due in part to statin intolerance or to the severity of cholesterol elevation, as seen in patients with familial hypercholesterolemia. With the availability of non-statin options, updated American College of Cardiology (ACC) Expert Consensus guidelines and National Lipid Association (NLA) recommendations now include PCSK9 inhibitors. Incorporating PCSK9 inhibitors and other non-statin therapies into clinical practice requires an understanding of new indications, guideline recommendations, and individualized patient strategies.

Please join us for Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know, a satellite symposium being held in Philadelphia in April 2019. This program is designed to help you apply the latest cholesterol-lowering national guidelines, and to assess the available evidence for non-statin options for patients who are not reaching lipid-lowering goals.

In this engaging, interactive, case-based symposium, a panel of renowned experts in dyslipidemia management will not only arm you with a knowledge of the latest clinical trial data on PCSK9 inhibitors, but they will also provide insights into the most challenging lipid-lowering scenarios for management of patients with CVD in your own practice. You will have the opportunity to question how the faculty members leverage existing clinical evidence to make decisions about selecting non-statin therapies for their patients, manage side effects, and adjust courses of treatment.

Benefits of Participating in This Engaging Program:

  • Expert interpretation of the latest national cholesterol-lowering guidelines
  • Guidance on issues of statin intolerance and severe hypercholesterolemia
  • Evidence-based strategies for management of dyslipidemia with non-statin therapies
  • Updates on indications for PCSK9 inhibitors and real-world experience to date
  • Network with your peers

Target Audience

This curriculum is directed toward all attendees of the 2019 ACP Meeting, including internists and internal medicine subspecialists. Nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment and management of patients with atherosclerosis may also attend and participate.

Learning Objectives

Upon successful completion of this activity, participants should have improved their ability to:

  • Interpret the latest guidelines and recommendations on cholesterol management from major clinical organizations
  • Determine when it is appropriate to use non-statin therapies
  • Compare potential cholesterol-lowering therapies beyond statins
  • Summarize in detail the indications for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy

Acknowledgment of Commercial Support

This activity is supported by an independent educational grant from Amgen.

Program Chair

Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY 10022

Become a Member

Forgot Password?
Calendar of Events
Filter By